Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Socioeconomic status transitions tied to dementia risk
May 23, 2024
The findings also show links to length of dementia-free periods over the lifespan.
American Academy of Neurology, April 13-18
Apr 23, 2024
The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians, academicians, allied health professionals,...
Lower risk for MCI, dementia seen with cognitively stimulating occupations
Apr 17, 2024
Participants in a high versus low routine task intensity group had a higher risk for mild cognitive impairment and dementia.
CDC shortens recommended COVID isolation period
Mar 01, 2024
New guidance issued Friday by the US Centers for Disease Control and Prevention recommends that Americans who test positive for COVID-19 no longer need to routinely stay home for five days.
Observed rates of cancer diagnoses lower than expected in pandemic
Feb 26, 2024
The rate of all-sites cancer incidence was 28.6% lower than expected during the height of the COVID-19 pandemic response.
American Stroke Association, Feb. 7-9
Feb 20, 2024
The conference featured presentations that emphasized basic, clinical and translational medicine and provided insight into the prevention, management and treatment of stroke.
Preexisting conditions seen in all patients with tachycardia after COVID-19 vaccine
Jan 10, 2024
Reduced heart rate variability was observed in patients with postvaccination postural orthostatic tachycardia syndrome.
Food insecurity in seniors linked to increased risk for dementia
Nov 21, 2023
Lower memory levels and faster age-related memory decline also were seen in association with low or very low food security.
Gantenerumab does not slow clinical decline in early Alzheimer’s disease
Nov 16, 2023
Two trials show a lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks.